CoChat

Endurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Context and objective: Obesity and inactivity are risk factors for developing impaired glucose tolerance characterized by insulin resistance and reduced beta-cell function. The stimulatory effect of glucagon-like peptide 1 (GLP-1) on insulin secretion is also impaired in obese, inactive individuals. The aim of this study was to investigate whether endurance training influences beta-cell sensitivity to GLP-1. Participants and intervention: Twenty-four female participants, age 46 ± 2 years, body mass index 32.4 ± 0.9 kg/m2, and maximal oxygen consumption 24.7 ± 0.8 mL/kg/min participated in a 10-week exercise training study. Methods: Beta-cell sensitivity to GLP-1 was assessed in a subset of participants (n = 6) during a 120-minute hyperglycemic glucose clamp (8.5 mM) including a 1-hour GLP-1 (7-36 amide) infusion (0.4 pmol/kg/min). Changes in glucose tolerance, body composition, and cardiorespiratory fitness were assessed by oral glucose tolerance tests (OGTTs), dual-energy X-ray absorptiometry scans, magnetic resonance scans, and maximal oxygen consumption (VO2max) tests, respectively. Results: The c-peptide response to infusion of GLP-1 increased 28 ± 3% (P < 0.05) toward the end of the hyperglycemic clamp. The insulin response remained unchanged. Training improved glucose tolerance and reduced GLP-1, insulin, and glucagon levels during the OGTTs. Training increased VO2max (from 24.7 ± 0.8 to 27.0 ± 0.7 mL/kg/min; P < 0.05) and reduced visceral fat volume (from 4176 ± 265 to 3888 ± 266 cm3; P < 0.01). Conclusion: Along with improved glycemic control, endurance training improved beta-cell sensitivity to GLP-1 in overweight women. The study was deemed not to constitute a clinical trial and was not registered as such.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jendso/bvac111

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Plasma concentration of (A) glucose, (B) glucagon-like peptide (GLP-1), (C) glucose infusion rate (GIR), (D) plasma concentration of insulin, (E) c-peptide, and (F) glucagon during a hyperglycemic clamp (~8.5 mmol/L) with GLP-1 infusion before and after a 10-week training period. Data are from 6 participants. Insulin, c-peptide, glucagon, and infusion rate data are presented as mean ± SEM. GLP-1 and glucose data are presented as geometric mean ± geometric SE. *Indicates a significant difference between the before and after trial at the specific time point (P < 0.05). /Indicates a significant effect of training (P < 0.05). $Indicates a significant change over time (P < 0.05). £Indicates a significant interaction between training and time (P < 0.05).
Figure 1. Plasma concentration of (A) glucose, (B) glucagon-like peptide (GLP-1), (C) glucose infusion rate (GIR), (D) plasma concentration of insulin, (E) c-peptide, and (F) glucagon during a hyperglycemic clamp (~8.5 mmol/L) with GLP-1 infusion before and after a 10-week training period. Data are from 6 participants. Insulin, c-peptide, glucagon, and infusion rate data are presented as mean ± SEM. GLP-1 and glucose data are presented as geometric mean ± geometric SE. *Indicates a significant difference between the before and after trial at the specific time point (P < 0.05). /Indicates a significant effect of training (P < 0.05). $Indicates a significant change over time (P < 0.05). £Indicates a significant interaction between training and time (P < 0.05).CC BY-NC-ND · PubMed Central
Figure 2. Plasma concentrations of (A) total glucagon-like peptide 1 (GLP-1), (B) intact glucose dependent insulinotropic peptide (GIP), (C) glucose, (D) c-peptide, (E) insulin, and (F) glucagon during an oral glucose tolerance test (OGTT) before and after a 10-week training period. (G) C-peptide: insulin, (H) Matsuda index, (I) insulinogenic index, and (J) disposition index before and after a 10-week training period. Data are from 24 participants and presented as geometric mean ± geometric SE. Matsuda index, insulinogenic and disposition index are presented as mean ± SEM. *Indicates significant difference between before and after training at the specific time point (P < 0.05). /Indicates significant effect of training (P < 0.05). $Indicates significant change over time (P < 0.05). £Indicates a significant interaction between training and time (P < 0.05).
Figure 2. Plasma concentrations of (A) total glucagon-like peptide 1 (GLP-1), (B) intact glucose dependent insulinotropic peptide (GIP), (C) glucose, (D) c-peptide, (E) insulin, and (F) glucagon during an oral glucose tolerance test (OGTT) before and after a 10-week training period. (G) C-peptide: insulin, (H) Matsuda index, (I) insulinogenic index, and (J) disposition index before and after a 10-week training period. Data are from 24 participants and presented as geometric mean ± geometric SE. Matsuda index, insulinogenic and disposition index are presented as mean ± SEM. *Indicates significant difference between before and after training at the specific time point (P < 0.05). /Indicates significant effect of training (P < 0.05). $Indicates significant change over time (P < 0.05). £Indicates a significant interaction between training and time (P < 0.05).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 18

Metadata

Authors
Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., Pedersen, B. K., & Ellingsgaard, H.
Affiliations
  • Centre of Inflammation and Metabolism and Centre for Physical Activity Research, Rigshospitalet, Copenhagen University Hospital – Rigshospitalet , DK 2100 Copenhagen , Denmark
  • University of Copenhagen (DK)
  • Copenhagen University Hospital (DK)
  • Rigshospitalet (DK)
  • Novo Nordisk (Denmark) (DK)
Corresponding author
Ellingsgaard, Helga
Venue
Journal of the Endocrine Society
Published
2022-07-26
Volume
6
Issue
9
Pages
bvac111-bvac111
ISSN
2472-1972 (ISSN-L)
OpenAlex
W4288036583
Cited by
15
References
51
Citations by year
2026: 4 · 2025: 6 · 2024: 1 · 2023: 4
FWCI
2.63
Type
journal article
Language
en
Open access
Locations
  • Journal of the Endocrine Society (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
Funders
  • Centre for Physical Activity Research
  • TrygFonden (ID 101390, ID 20045, ID 125132)
  • Centre of Inflammation and Metabolism
  • Danish National Research Foundation (#02-512-55)
  • Commission of the European Communities (LSHM-CT-2004-005272)
  • Danish Medical Research Council
  • Carla Thiel Kragh Foundation
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
endurance training, glucagon-like peptide-1, glucose tolerance, overweight women, obesity, insulin resistance, C-peptide response, visceral fat, cardiorespiratory fitness, oral glucose tolerance test

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.